2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-167884
    PF-1367550 319461-60-4 98%
    PF-1367550 is a pan-JAK inhibitor. PF-1367550 can decrease the levels of release of CXCL9, CXCL10 and CXCL11 from primary airway epithelial cells.
    PF-1367550
  • HY-168053
    HMGB1-IN-3 5195-71-1 98%
    HMGB1-IN-3 (compound E) is a glycyrrhizic acid derivative with strong inhibitory activity against HMGB1 (high mobility group protein 1) and can be used in the study of intracerebral hemorrhage.
    HMGB1-IN-3
  • HY-168211
    LQ-38 98%
    LQ-38 is an orally active inhibitor for soluble epoxide hydrolase (sEH) with an IC50 of 5.2 nM. LQ-38 exhibits anti-inflammatory activity in rat foot edema model and mouse acute pancreatitis model, exhibits analgesic effect in Acetic acid (HY-Y0319)-induced writhing mouse model.
    LQ-38
  • HY-168360
    Bufotenidine iodide 5787-02-0 98%
    Bufotenidine iodide is a component found in toad venom and belongs to the indole alkaloid class.
    Bufotenidine iodide
  • HY-168361
    8β-Hydroxy-exo-THC 52522-55-1 98%
    8β-Hydroxy-exo-THC is a cannabinoid ether analogue with a weaker affinity for receptor sites, with an IC50 of 1.2 μM.
    8β-Hydroxy-exo-THC
  • HY-168369
    Anti-inflammatory agent 94 501927-29-3 98%
    Anti-inflammatory agent 94 (compound 4b) is a potent cannabinoid ligand with Kis of 29 nM and 8 nM against CB2 and CB1. Anti-inflammatory agent 94 can be utilized in inflammation rersearch.
    Anti-inflammatory agent 94
  • HY-168384
    M04 875158-73-9 98%
    M04 is an agonist of STING. It induces the expression of the IFN reporter gene in HEK293T cells expressing wild-type human STING, but does not induce this expression in HEK293T cells expressing the R71H-G230A-R293Q (HAQ) STING variant or in mouse RAW 264.7 cells, indicating that its activity is dependent on allelic and species variations. M04 induces the production of TNF-α, IL-10, IL-1β, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs). At a concentration of 50 µM, M04 stimulates dendritic cells isolated from PBMCs to express the MHC class II cell surface receptor HLA-DR and co-stimulatory molecules CD40, CD80, and CD86, and also enhances their ability to activate T cells in an ex vivo assay. M04 can be used in research on inflammatory immune diseases.
    M04
  • HY-168520
    NLRP3-IN-57 98%
    NLRP3-IN-57 (compound 5) inhibits the NLRP3 inflammasome, thereby reducing IL-1β levels in LPS plus Nigericin-induced THP-1 macrophages..
    NLRP3-IN-57
  • HY-168561
    NLRP3-IN-58 2956014-05-2 98%
    NLRP3-IN-58 (Compound DS15) is an inhibitor for the activation of NLRP3 inflammasome with an IC50 of 3.85 μM, and inhibits 33% IL-1β release at a concentration of 10 μM.
    NLRP3-IN-58
  • HY-168766
    O-Acetylsalicylhydroxamic acid 199854-00-7 98%
    O-Acetylsalicylhydroxamic acid is an acetylation inhibitor of prostaglandin H2 synthase that can suppress PGE2 synthesis in the body and block the cyclooxygenase activity of PGHS in vitro. O-Acetylsalicylhydroxamic acid requires the presence of the active site residue Ser-529 to act on human PGHS-1; the S529A mutant is resistant to the inactivation effects of this inhibitor.
    O-Acetylsalicylhydroxamic acid
  • HY-168782
    Resolvin D2 n-3 DPA 2093111-29-4 98%
    Resolvin D2 n-3 DPA is a specialized proresolving mediator (SPM). Resolvin D2 n-3 DPA (1 nM) can reduce the chemotaxis and adhesion of human neutrophils induced by TNF-α. Resolvin D2 n-3 DPA (100 ng/mouse; intravenous injection) can reduce neutrophil infiltration in the peritoneum and the levels of IL-6 and the chemokine (C-C motif) ligand 2 (CCL2) in a mouse model of inflammation induced by zinc oxide.
    Resolvin D2 n-3 DPA
  • HY-168784
    LTD4 antagonist 2 107813-86-5 98%
    LTD4 antagonist 2 (compound 6) is a leukotriene D4 (LTD4) antagonist with an IC50 of 2.8 μM against cysteinyl leukotriene 1 receptor (CysLT1R). LTD4 antagonist 2 is also a G protein-coupled bile acid receptor 1 (GPBAR1) agonist and can be utilized in research related to colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases.
    LTD4 antagonist 2
  • HY-168955
    Antibacterial agent 269 98%
    Antibacterial agent 269 (3.8) is an inhibitor of AdeG Efflux Pumps in Acinetobacter baumannii.
    Antibacterial agent 269
  • HY-169132
    Anti-MRSA agent 17 98%
    Anti-MRSA agent 17 (8) is an inhibitor against S. aureus (MRSA) BPL (SaBPL), with a Ki of 10.3 nM.
    Anti-MRSA agent 17
  • HY-169536
    CFTR activator 2 871700-29-7 99.54%
    CFTR activator 2 (WAY-326769) is an activator of mutant cystic fibrosis transmembrane conductance regulator (mutant-CFTR).
    CFTR activator 2
  • HY-169555
    ASK1-IN-7 1427537-92-5 98%
    ASK1-IN-7 (Compound 4c) is an ASK1 inhibitor and a derivative of the ASK1 inhibitor scaffold 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one. ASK1-IN-7 holds promise for research related to the ASK1 signaling pathway, such as cell stress responses, inflammation, neurodegenerative diseases, and cardiovascular diseases.
    ASK1-IN-7
  • HY-169602
    GSK-3β inhibitor 26 70169-39-0 98%
    GSK-3β inhibitor 26 (Compound D14) is a GSK-3β inhibitor with an IC50 of 18.23 μM. GSK-3β inhibitor 26 can be used in the research of cancer, inflammation and neurodegenerative diseases.
    GSK-3β inhibitor 26
  • HY-169674
    JNK-IN-20 346663-56-7 98%
    JNK-IN-20 (compound 5) is a JNK inhibitor. JNK-IN-20 can be used in inflammation and tumor related research.
    JNK-IN-20
  • HY-169678
    GRK6-IN-5 33495-39-5 98%
    GRK6-IN-5 is a GRK6 polypeptide inhibitor, with IC50 value of 4.48 μΜ. GRK6-IN-5 can be used to study hematological malignancies, inflammation diseases, and autoimmune disorders.
    GRK6-IN-5
  • HY-169685
    p38 MAPK-IN-6 421578-44-1 98%
    p38 MAPK-IN-6 (compound c47) is a p38 MAPK inhibitor. p38 MAPK-IN-6 shows 14% inhibition at 10 μM.
    p38 MAPK-IN-6
Cat. No. Product Name / Synonyms Application Reactivity